Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.59 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | KDM5A | P29375 | 1/20 | 0.59 |
| ▸ | KDM5C | P41229 | 1/20 | 0.59 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220154 | 0.90 | RAB9A (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4142247 | 0.84 | APP (0.50) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23753416 | 0.82 | APP (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14658714 | 0.81 | LPL (0.40) | LPLLIPG | |
| SCHEMBL1726545 | 0.80 | RAB9A (0.56) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20480347 | 0.79 | PIK3CG (0.47) | LPLLIPG | |
| SCHEMBL2063708 | 0.78 | ALDH1A3 (0.57) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL218127 | 0.77 | LPL (0.39) | LPLLIPG | |
| SCHEMBL396368 | 0.76 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2063814 | 0.75 | LPL (0.42) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262804-B1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8148370-B2 | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-8148370-B2 | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-01 | — | — | US | disclosed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| WO-2009144392-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144391-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | NPC1 1704/4885RAB9A 1592/4885ALDH1A1 765/4885 |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | NPC1 1704/4885RAB9A 1592/4885ALDH1A1 765/4885 |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NPC1 1125/4885RAB9A 1452/4885ALDH1A1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.